October 2025 saw a wave of M&As and biotech deals in various therapeutic fields, particularly for therapies addressing ...

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

The companies Kailera Therapeutics, Summit Therapeutics, and Tubulis bagged the biggest biotech funding rounds overall in ...

Pichia pastoris is emerging as a versatile, efficient alternative for protein production, bridging microbial and mammalian expression systems.

From growing mini-organs to reviving the dodo and gene-editing embryos, boundaries between sci-fi and today's advances are ...

Discover eight key AI biotech deals that have been made so far in 2025, spotlighting where industry leaders are betting big.

Once a booming field, bustling with innovation and money driving that innovation, the cell and gene therapy sector is now struggling to fuel therapeutic growth to bring medicines to patients. It doesn ...

The news that the organization led a $35 million funding round for London-based Portal Biotech came about two weeks ago. Portal Biotech’s focus is on the field of proteomics, which is the study of ...

When Turnstone Biologics was founded, its team had high hopes for the California-based biotech to “lead the fight against solid tumors.” At first, it was keen on developing oncolytic viruses, which ...

In 2020, Novo Nordisk’s Canadian patent for semaglutide, the active ingredient in its blockbuster GLP-1 drugs Ozempic and Wegovy, quietly expired. The reason? A small missed maintenance fee, ...

Migraines are not simply a bad headache; they are a neurological disorder that can significantly impact daily life. Often characterized by throbbing pain on one side of the head, they can be moderate ...